Evaluating the efficacy and safety of MDMA for the treatment of Post Traumatic Stress Disorder: a systematic review
UCC Student Medical Journal – October 17, 2025
Source: OpenAlex
Summary
MDMA-assisted psychotherapy shows promise for treating PTSD, with significant symptom reductions observed in 67 participants compared to placebo. Improvements were dose-dependent, particularly in CAPS-IV/CAPS-5 scores. Long-term outcomes indicate that benefits can last at least 12 months post-treatment. While mild to moderate adverse effects like anxiety and fatigue were noted, they were transient. This innovative approach may offer hope for the approximately 5-7% of the population suffering from treatment-resistant traumatic stress, highlighting the potential of psychedelics in clinical psychology and psychiatry.
Abstract
Background: Posttraumatic stress disorder (PTSD) affects approximately 5-7% of the population, with conventional treatments often proving inadequate for some patients. Recent studies suggest that methylenedioxymethamphetamine (MDMA) combined with psychotherapy may offer a novel therapeutic approach. This systematic review evaluates the efficacy and safety of MDMA-assisted psychotherapy for the treatment of PTSD in individuals with chronic, treatment-resistant forms of the disorder. Methods: A comprehensive search was conducted in PubMed, OVID, Scopus, Cochrane databases, and select reference lists for randomized controlled trials (RCTs) evaluating MDMA as a treatment for PTSD. Eligibility criteria included RCTs with participants with confirmed PTSD diagnoses using standardized clinical assessments. Results: In the RCT studies, there are significant reductions in PTSD symptoms (p<0.05) in those with MDMA-assisted psychotherapy compared to those with placebo and psychotherapy; dose-dependent improvements were observed in various measurements scales (specifically in CAPS-IV/CAPS-5 scores). Open-label trials further demonstrated improvements in PTSD symptoms when given MDMA-assisted therapy (p<0.05) and long-term analyses of studies demonstrated that effects of MDMA-assisted therapy were maintained for a minimum of 12 months post-intervention(p<0.05). Adverse effects were transient and mild to moderate, including anxiety, headache, fatigue, muscle tension, and insomnia. Conclusion: Extant data suggests that MDMA-assisted psychotherapy for PTSD demonstrates significant symptom reduction, with sustained efficacy up to 12 months post-treatment. Functional unblinding is a major methodological challenge, which makes it difficult to interpret the magnitude of the effect MDMA has in the treatment of treatment-resistant PTSD. Future research should refine methodologies and explore long-term safety and efficacy in diverse populations.